
    
      This clinical trial is a prospective, randomized, controlled, multicenter study in patients
      who are capable of using and consent to use a smartphone-based ECG monitoring after ablation
      for atrial fibrillation. The patients will be randomly assigned to either the Holter
      monitoring or ICT-based centralized clinical trial monitoring system group in a 1:1 ratio and
      will undergo monitoring from immediately after the procedure to 12 months after discharge.
    
  